For & Against

Figures converted from HKD at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

What's Next

The next six months hinge on a single data point: Blue Moon's H1 2026 selling expense ratio. Everything else — the buyback, the dividend, the analyst upgrades — is noise until that number prints.

No Results

What the market is watching most closely: The H1 2026 interim results, expected August 2026. Both the bull and bear cases collapse or confirm on the S&D ratio. Bull needs it below 48% with stable revenue. Bear expects it back above 50%. Q4 2025's quarterly profit of $7M was encouraging but covered just one quarter — the interim will show whether cost discipline survives a full half-year.

China's regulatory push toward concentrated detergent formats and energy-efficient washing provides a modest structural tailwind for Blue Moon's Zhizun product line, but it is a slow-moving industry trend, not a near-term catalyst.

For / Against / My View

For

Bull price target: $0.64 (60% upside from $0.40). Timeline: 18–24 months through FY2026 and FY2027 results seasons. Methodology: 30x P/E on ~$116M FY2027E normalized net income, assuming S&D normalizes to 38% of revenue. Disconfirming signal: S&D ratio re-accelerating above 55% in any reported half-year.

Against

Bear downside target: $0.23 (42% downside from $0.40). Timeline: 12–18 months through H1 2027 results. Methodology: EV/Sales compression to 1.0x on flat $1,080M revenue with net cash reduced to ~$321M after 12 months of burn. Trigger: H1 2026 S&D ratio above 50%, confirming FY2025 was transient. Covering signal: two consecutive quarters of S&D below 45% with stable or growing revenue.

The Tensions

1. S&D at 53%: structural inflection or revenue sacrifice?

Bull says the 6-percentage-point improvement from 59% to 53% proves the company can control costs, and each further point adds $11M to operating income. Bear says the improvement came with a 1.7% revenue decline — the company spent less because it sold less, not because it became more efficient. Both cite the same number: FY2025 S&D at 53.1% of revenue on $1,080M in sales. This resolves on the H1 2026 interim results: if S&D falls below 48% while revenue holds flat or grows, the inflection is structural. If revenue falls further to achieve the next S&D reduction, it is not.

2. Pan Dong's 73.78%: alignment or extraction?

Bull says the founder has suffered $5.5B in paper losses and authorized a $231M buyback, proving she views the stock as deeply undervalued and her interests are aligned with minorities. Bear says Pan Dong has received approximately $385M in dividends through her 73.78% stake — funded from IPO proceeds, not earnings — while the business lost money in two of the last three years. Both cite the same fact: a 74% founder who controls all capital allocation decisions. This resolves on whether the buyback is executed at meaningful scale and whether dividends are cut when the cash pile drops below $321M — or whether founder extraction continues regardless.

3. The FY2025 partial: first promise kept, or five-year pattern?

Bull points to the FY2025 loss reduction of 56%, the Q4 quarterly profit of $7M, and the buyback authorization as evidence that management has finally delivered. Bear points to four consecutive years of missed profitability guidance (FY2021–FY2024), the appearance and disappearance of non-HKFRS metrics, and the retroactive "strategic investment" reframe — arguing one partial delivery does not break a five-year pattern. Both cite the same management track record. This resolves on whether H1 2026 results match or exceed the forward guidance management provides over the next three months — one more miss and the pattern is cemented.

My View

I lean cautious. The Against side is heavier here — not because the product is bad (the 60% gross margin is real and structurally impressive), but because the stock at $0.40 already trades 25% above analyst consensus and prices in a turnaround that has only one quarter of supporting evidence after five years of deterioration. The central tension — whether S&D at 53% is an inflection or a one-year cut achieved by shrinking revenue — tips the scale toward waiting. Management's credibility deficit after four straight misses means the FY2025 improvement needs confirmation before it earns the benefit of the doubt. I would wait for H1 2026 results: if S&D prints below 48% on flat or growing revenue, the setup becomes genuinely compelling and worth revisiting. Until then, the risk-reward favors patience over conviction.